Financial Performance - The group's revenue decreased by approximately RMB 241.7 million or 20.4% to about RMB 943.3 million for the year ended December 31, 2025[3]. - Gross profit fell by approximately RMB 177.2 million or 19.8% to about RMB 717.0 million compared to the year ended December 31, 2024[3]. - EBITDA decreased by approximately RMB 112.0 million or 22.9% to about RMB 377.1 million for the year ended December 31, 2025[3]. - Profit attributable to equity holders decreased by approximately RMB 67.4 million or 21.2% to about RMB 251.2 million compared to the previous year[3]. - Total comprehensive income for the year was RMB 249.0 million, down from RMB 319.4 million in the previous year[5]. - The company's revenue for the year ending December 31, 2025, was approximately RMB 943.3 million, a decrease of about RMB 241.7 million or 20.4% compared to RMB 1,185.0 million for the year ending December 31, 2024, primarily due to adjustments in marketing strategies leading to reduced procurement by distributors[49]. - Net profit for the year ending December 31, 2025, was approximately RMB 251.2 million, a decrease of RMB 67.4 million or 21.2% compared to RMB 318.6 million for the year ending December 31, 2024[62]. Assets and Liabilities - Non-current assets increased to RMB 513.4 million from RMB 495.0 million in the previous year[6]. - Current assets totaled RMB 1,775.7 million, slightly up from RMB 1,756.2 million in 2024[6]. - The net asset value decreased to RMB 1,376.7 million from RMB 1,466.3 million in the previous year[7]. - Total bank loans and other borrowings amounted to RMB 584.266 million as of December 31, 2025, compared to RMB 426.916 million as of December 31, 2024[25]. - The current ratio decreased from 2.5 on December 31, 2024, to 2.2 on December 31, 2025, with net current assets of approximately RMB 957.4 million[63]. - Total interest-bearing bank and other borrowings increased from approximately RMB 426.9 million as of December 31, 2024, to approximately RMB 584.2 million as of December 31, 2025, an increase of RMB 157.3 million[64]. - The debt-to-equity ratio increased from approximately 29.1% on December 31, 2024, to approximately 42.4% on December 31, 2025[66]. Revenue Sources - Total revenue from external customers decreased to RMB 943,258,000 in 2025 from RMB 1,185,004,000 in 2024, representing a decline of approximately 20.4%[12]. - Revenue from a major customer (Customer A) decreased to RMB 137,410,000 in 2025 from RMB 148,375,000 in 2024, a decline of about 7.9%[13]. - Revenue from the sales of Jin Sang Zi throat lozenges (OTC) was approximately RMB 873.0 million, down RMB 222.3 million or 20.3% from RMB 1,095.3 million in the previous year, attributed to a decline in sales volume[49]. - Revenue from the sales of Jin Sang Zi throat treasure series products was approximately RMB 65.3 million, a decrease of RMB 21.4 million or 24.7% compared to RMB 86.7 million in the previous year, also due to a decline in sales volume[49]. - The flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 92.6% of the total revenue for the year ending December 31, 2025[30]. - The sales of other products accounted for approximately 0.5% of the total revenue for the year ending December 31, 2025[33]. Expenses and Costs - The pre-tax profit before deductions was impacted by a decrease in the cost of sales to RMB 226,248,000 in 2025 from RMB 290,820,000 in 2024, a reduction of approximately 22.2%[17]. - Total financial costs decreased slightly to RMB 14,384,000 in 2025 from RMB 15,363,000 in 2024, a decline of about 6.4%[18]. - Income tax expense for the year was RMB 77,658,000 in 2025, down from RMB 118,647,000 in 2024, a decrease of approximately 34.5%[19]. - Selling and distribution expenses were approximately RMB 313.5 million for the year ending December 31, 2025, down RMB 42.4 million or 11.9% from approximately RMB 355.9 million for the year ending December 31, 2024[57]. - Administrative expenses decreased from approximately RMB 117.1 million for the year ending December 31, 2024, to approximately RMB 96.8 million for the year ending December 31, 2025, a reduction of RMB 20.3 million or 17.3%[58]. - The sales cost decreased from approximately RMB 290.8 million for the year ending December 31, 2024, to approximately RMB 226.2 million for the year ending December 31, 2025, primarily due to a reduction in sales volume of Jin Sang Zi throat lozenges (OTC)[52]. Product Development and Market Strategy - The company is focusing on expanding its product range and enhancing organizational capabilities to strengthen its market position in the throat lozenge market and increase its market share in China's pharmaceutical and food sectors[45]. - The company plans to maintain and promote its "Jin Sang Zi" brand to enhance brand recognition and image in China, aiming to make it a household name for effective and safe throat lozenge products[47]. - The company is developing a new product line, Jin Sang Zi propolis soothing spray, designed for throat discomfort, which will be primarily sold through online platforms[44]. - The company is investing in the development of probiotics with proprietary strains and advanced technologies, aiming to capture the growing health-conscious consumer market in China[43]. - The company has diversified its product offerings with the Jin Sangzi throat treasure series, which includes sugar-free options to cater to different consumer preferences[31]. - The new product, Jin Sangzi Propolis Soothing Spray, was launched in 2025, targeting throat discomfort with herbal ingredients and is primarily sold online[33]. Digital Presence and Expansion - The company has established an online flagship store for Jin Sangzi throat treasure on Tmall, enhancing its digital presence and product accessibility[32]. - The company continues to adapt to the online consumption trend, having established flagship stores on platforms like Tmall and WeChat, with plans for further expansion in online sales channels by 2025[46]. - The company has expanded its international presence, exporting products to over 60 countries, with new markets including South Korea, Peru, Ecuador, and Uzbekistan in 2025[37]. - The distribution network covers all provinces and municipalities in China, with a focus on enhancing cooperation with key distributors and online pharmacies[38]. - The company has signed agency agreements with all 10 ASEAN countries, successfully exporting products to nine of them[39]. - The company has established promotional agreements with 11 promoters to leverage local market knowledge and enhance product visibility[40]. Corporate Governance and Management - The board proposed a final dividend of HKD 0.34 per share, subject to approval at the upcoming annual general meeting[3]. - The company secretary, Ms. Li, has resigned effective March 27, 2026, with no disagreements reported with the board[86]. - Ms. Qu has been appointed as the new company secretary, effective March 27, 2026, bringing over ten years of experience in corporate secretarial services[87]. - The board expresses gratitude to Ms. Li for her contributions during her tenure and welcomes Ms. Qu to her new role[88]. Future Outlook and Investments - The group plans to continue strengthening its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors in 2026[74]. - The group has committed to invest approximately RMB 154 million in the construction of a new pharmaceutical production and R&D base in Liuzhou, Guangxi, by December 31, 2025[72]. - The second phase of the new base, covering 50,000 square meters, is under construction and will include a health industry production facility and R&D center, expected to enhance innovation in health products[48]. - The group is actively enhancing its production capacity, expanding its product portfolio, and strengthening R&D capabilities to promote synergy among different product segments[74]. - The unutilized proceeds from the initial public offering are expected to be fully utilized by 2028[77]. - The financial data presented does not constitute audited accounts for the year ending December 31, 2025, but is extracted from the consolidated financial statements reviewed by the auditor, Ernst & Young[84]. - The audited annual results and the 2025 annual report will be published on the Stock Exchange and the company's website in due course[85].
金嗓子(06896) - 2025 - 年度业绩